GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
GRAIL, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.42+4.61 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
GRAIL, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening revenue | $157.56M | $149.30M | $138.60M | $127.87M | $120.44M | $114.22M | $108.63M | – | – | – | – | 95.3% | +30.8% |
| Development Services | $7.70M | $6.82M | $8.57M | $13.96M | $13.85M | $16.49M | $16.97M | $17.94M | $18.64M | $17.22M | $18.11M | 4.7% | -44.4% |
By region
From the segment and revenue-disaggregation notes of Grail's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.